Skip to main content
Top
Published in: Clinical Oral Investigations 2/2018

01-03-2018 | Review

Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol

Authors: Luca Ramaglia, Agostino Guida, Vincenzo Iorio-Siciliano, Alessandro Cuozzo, Andrea Blasi, Anton Sculean

Published in: Clinical Oral Investigations | Issue 2/2018

Login to get access

Abstract

Objective

The most debated topic about medication-related osteonecrosis of the jaws (MRONJ) is its therapy, as there are no definitive guidelines. The aims of this systematic review were (a) to outline the best therapeutic approach according to the stage at diagnosis and (b) to perform a meta-analysis to assess whether the drug-holiday protocol may be or not an effective method in the management of MRONJ patients.

Materials and methods

The systematic review was performed following the PRISMA principles. Results were screened according to inclusion and exclusion criteria regarding staging before/after treatment, follow-up, and information provided by the authors. For statistical analysis, linear variables are reported as means and standard deviations, medians, and inter-quartile range (IQR); normality of data, according to the distribution of complete healing (primary outcome variable), was assessed with the Kolmogorov-Smirnov test. A p value < 0.05 was considered statistically significant for all tests.

Results

Thirteen studies were selected out of 1480. None of them was case-controlled or randomized. Conservative approach showed good results at early stages, but heterogeneous result at advanced stages (100% stage 0, stage I range 81–97%, stage II range 63.6–100%, stage III 73%). Surgical approach showed heterogeneous results at all stages (stage I range 0–100%, stage II range 52–100%, stage III range 50–100%). Statistical analysis showed a significantly higher prevalence of completely healed sites in patients who followed the drug-holiday protocol.

Conclusions

The results suggest that the current stage-specific approach for MRONJ therapy is based on a sound clinical rationale. Conservative treatment appears to yield better outcomes at early stages, while further investigations are needed to elucidate the best protocols for the management of advanced stages. The drug-holiday protocol statistically promotes complete healing after oral surgery procedures but the application should be dictated by the condition of each patient.

Clinical relevance

At present, early MRONJ stages should be primarily treated by means of a conservative approach while more advanced stages must be carefully evaluated. Individual decisions should be made for every single case even with respect to the drug-holiday protocol.
Literature
3.
go back to reference Roger MJ, Gordon S, Benford HL (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 supplement):2961–2978CrossRef Roger MJ, Gordon S, Benford HL (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 supplement):2961–2978CrossRef
4.
go back to reference Stresing V, Daubiné F, Benzaid I (2007) Bisphosphonates in cancer therapy. Cancer Lett 257:16–35CrossRefPubMed Stresing V, Daubiné F, Benzaid I (2007) Bisphosphonates in cancer therapy. Cancer Lett 257:16–35CrossRefPubMed
5.
go back to reference Santini D, Vincenzi B, Avvisati G (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080–1084PubMed Santini D, Vincenzi B, Avvisati G (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080–1084PubMed
7.
go back to reference Ruggiero SL, Mehrotra B, Rosenberg TJ (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534CrossRefPubMed Ruggiero SL, Mehrotra B, Rosenberg TJ (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534CrossRefPubMed
8.
go back to reference Hellstein JW, Marek CL (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63:682–689CrossRefPubMed Hellstein JW, Marek CL (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63:682–689CrossRefPubMed
11.
go back to reference Min You T, Lee KH, Lee SH (2015) Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 120:548–553CrossRef Min You T, Lee KH, Lee SH (2015) Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 120:548–553CrossRef
12.
go back to reference Santos-Silva AR, Belizario Rosa GA, Castro GD (2013) Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 115:E32–E36CrossRefPubMed Santos-Silva AR, Belizario Rosa GA, Castro GD (2013) Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 115:E32–E36CrossRefPubMed
13.
go back to reference Ramírez L, López RM, Casañas E (2015) New non-bisphosphonate drugs that produce osteonecrosis of the jaws. Oral Health Prev Dent 13:385–393PubMed Ramírez L, López RM, Casañas E (2015) New non-bisphosphonate drugs that produce osteonecrosis of the jaws. Oral Health Prev Dent 13:385–393PubMed
18.
go back to reference Otto S, Schreyer C, Hafner S (2012) Bisphosphonate-related osteonecrosis of the jaws—characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 40:303–309CrossRefPubMed Otto S, Schreyer C, Hafner S (2012) Bisphosphonate-related osteonecrosis of the jaws—characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 40:303–309CrossRefPubMed
19.
go back to reference Lee CY, David T, Nishime M (2007) Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantol 33(6):371–382CrossRefPubMed Lee CY, David T, Nishime M (2007) Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantol 33(6):371–382CrossRefPubMed
20.
go back to reference Ruggiero SL, Dodson TB, Leon A (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw—2009 update. J Oral Maxillofac Surg 67:2–12CrossRefPubMed Ruggiero SL, Dodson TB, Leon A (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw—2009 update. J Oral Maxillofac Surg 67:2–12CrossRefPubMed
23.
go back to reference Bocanegra-Pèrez S, Barrero MV, Hernández MS (2008) Bisphosphonate-associated osteonecrosis of the jaw. A proposal for conservative treatment. Med Oral Patol Oral Cir Bucal 13:E770–E773 Bocanegra-Pèrez S, Barrero MV, Hernández MS (2008) Bisphosphonate-associated osteonecrosis of the jaw. A proposal for conservative treatment. Med Oral Patol Oral Cir Bucal 13:E770–E773
24.
go back to reference Agrillo A, Filiaci F, Ramieri V (2012) Bisphosphonate-related osteonecrosis of the jaw (BRONJ) 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci 16:1741–1747PubMed Agrillo A, Filiaci F, Ramieri V (2012) Bisphosphonate-related osteonecrosis of the jaw (BRONJ) 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci 16:1741–1747PubMed
31.
go back to reference Rincón H, Rodríguez Z, Tambay C (2007) Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic recommendations. Med Oral Patol Oral Cir Bucal 12:E267–E271 Rincón H, Rodríguez Z, Tambay C (2007) Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic recommendations. Med Oral Patol Oral Cir Bucal 12:E267–E271
32.
go back to reference Van den Wyngaert T, Claeys T, Huizing MT (2009) Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 20:331–336CrossRefPubMed Van den Wyngaert T, Claeys T, Huizing MT (2009) Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 20:331–336CrossRefPubMed
38.
go back to reference Eckardt AM, Lemound J, Lindhorst D (2011) Surgical management of bisphosphonate-related osteonecrosis of the jaw in oncologic patients—a challenging problem. Anticancer Res 31(6):2313–2318PubMed Eckardt AM, Lemound J, Lindhorst D (2011) Surgical management of bisphosphonate-related osteonecrosis of the jaw in oncologic patients—a challenging problem. Anticancer Res 31(6):2313–2318PubMed
39.
go back to reference Vescovi P, Merigo E, Meleti M (2014) Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw. Int J Dent 2014:107690CrossRefPubMedPubMedCentral Vescovi P, Merigo E, Meleti M (2014) Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw. Int J Dent 2014:107690CrossRefPubMedPubMedCentral
48.
go back to reference Mozzati M, Gallesio G, Pol R (2013) A report on a 7-year follow up of the surgical management with PRGF-ENDORET® of oncologic patients affected by intravenous bisphosphonate related osteonecrosis of the jaw. Surgery S12:011 Mozzati M, Gallesio G, Pol R (2013) A report on a 7-year follow up of the surgical management with PRGF-ENDORET® of oncologic patients affected by intravenous bisphosphonate related osteonecrosis of the jaw. Surgery S12:011
Metadata
Title
Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol
Authors
Luca Ramaglia
Agostino Guida
Vincenzo Iorio-Siciliano
Alessandro Cuozzo
Andrea Blasi
Anton Sculean
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Clinical Oral Investigations / Issue 2/2018
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-017-2325-6

Other articles of this Issue 2/2018

Clinical Oral Investigations 2/2018 Go to the issue